RenalytixRENXF OCF Yield % is -116.04 as of Jun. 30, 2026. The stock has 3 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Renalytix ranks worse than 97.07% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Renalytix's OCF Yield % or its related term are showing as below:
RENXF'
s OCF Yield % Range Over the Past 10 Years
Min: -309.32 Med: -74.82 Max: -2.18
Current: -116.04
During the past 8 years, the highest OCF Yield % of Renalytix was -2.18%. The lowest was -309.32%. And the median was -74.82%.
RENXF's OCF Yield % is ranked worse than 97.07% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 5.51
vs RENXF: -116.04
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Renalytix OCF Yield % Related Terms
Renalytix OCF Yield % Historical Data
* Premium members only.
The historical data trend for Renalytix's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Renalytix's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Renalytix OCF Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Renalytix's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Renalytix (RENXF) has a OCF Yield % of -116.04 as of Jun. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Renalytix and its competitors. According to the industry distribution chart, Renalytix ranks #663 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 97.1%.
Is Renalytix's OCF Yield % too high?
Renalytix's current OCF Yield % is -116.04. Based on the distribution chart, Renalytix ranks #663 out of 683 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers.
How does Renalytix's OCF Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Renalytix ranks #663 out of 683 companies for OCF Yield %. This places Renalytix in the lower half of its industry. The industry median OCF Yield % is 5.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Healthcare Providers & Services company?
The median OCF Yield % among Healthcare Providers & Services companies is 5.51, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Renalytix and its competitors. For the Healthcare Providers & Services industry, the median OCF Yield % is 5.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Renalytix's current OCF Yield % is -116.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Renalytix stock overvalued right now?
Based on GuruFocus' analysis, Renalytix (RENXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.10, compared to a current price of $0.04 — trading 63.9% below its estimated fair value. The current OCF Yield % is -116.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Renalytix (RENXF), the current OCF Yield % is -116.04 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RENXF has been successfully added to your 